Lenalidomide Teva

Lenalidomide, the active ingredient in Lenalidomide Teva, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for systemic use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable sourcing for hospitals, pharmacies and clinical trial sites across multiple regions.

Lenalidomide is indicated for several hematologic malignancies and works within the disease pathways of abnormal plasma cell proliferation and dysplastic bone marrow clones. - Multiple myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients. - Mantle cell lymphoma: contributes to disease control when used in combination regimens for relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: decreased neutrophil count leading to infection risk. - Thrombocytopenia: reduced platelet levels causing easy bruising. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe infections: opportunistic or life‑threatening bacterial, viral or fungal infections.

Before initiating Lenalidomide therapy, clinicians should observe several precautionary measures to minimize risks. - Pregnancy contraindication: drug is teratogenic (Category X) and requires effective contraception for both sexes. - Contraception requirement: use two reliable methods of birth control during treatment and for at least four weeks after the last dose. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Thromboembolic risk: assess need for prophylactic anticoagulation in patients with additional risk factors. - Renal and hepatic function: evaluate organ function and adjust dose if impairment is present. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure and toxicity. - Thalidomide or pomalidomide combined use: additive teratogenic risk and overlapping toxicities. - Warfarin: potentiates anticoagulant effect, raising bleeding risk. - Live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower lenalidomide plasma levels, reducing effectiveness. - NSAIDs: combined use can increase risk of gastrointestinal bleeding. - Anticoagulants (e.g., apixaban): monitor for enhanced anticoagulant effect. - Antifungal azoles (e.g., fluconazole): may modestly raise lenalidomide concentrations.